Get the Stockscreener App
24.61
6.77%
1.56
After Hours:
24.93
0.32
+1.30%
Summit Therapeutics Inc stock is traded at $24.61, with a volume of 3.44M.
It is up +6.77% in the last 24 hours and up +22.26% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$23.05
Open:
$22.96
24h Volume:
3.44M
Relative Volume:
1.20
Market Cap:
$19.28B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-102.54
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
+22.13%
1M Performance:
+22.26%
6M Performance:
+14.09%
1Y Performance:
+589.36%
1-Day Range:
$22.86
$24.99
1-Week Range:
$20.16
$26.23
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
24.61 | 19.28B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Truist maintains Buy on Summit Therapeutics, $35 target By Investing.com - Investing.com Canada
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
U.S. Indexes Rose Monday; Summit Therapeutics Led Increases - Barron's
Here's Why Summit Therapeutics Stock Soared 15% on Friday - MSN
Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer - Yahoo Finance
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (SMMT) - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - MSN
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX - MSN
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Summit Therapeutics Inc. (SMMT) Soared Last Week? - Insider Monkey
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics: Not Pharmacyclics, Not Yet - Seeking Alpha
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
U.S. Indexes Moved Upward Friday; Summit Therapeutics Led Increases - Barron's
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald - Yahoo Finance
Expert says Summit’s HARMONi-2 study could beat expectations, says Truist - Yahoo Finance
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Summit Therapeutics (SMMT) Shows Resilient Cash Management Amid Challenges - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? - Insider Monkey
Summit Therapeutics (SMMT) Sees Stock Surge Amid Early Warrant E - GuruFocus
10 Firms Buck Thursday’s Market Bloodbath - Insider Monkey
Summit Therapeutics (SMMT) Shares Surge After Insider Actions - GuruFocus
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - MSN
Summit Therapeutics Shares Surge Amid Study Optimism - TipRanks
Summit Therapeutics (SMMT) Expected to Deliver Strong Results fr - GuruFocus
Summit Therapeutics (SMMT) Sees Bullish Surge as Co-CEO Exercise - GuruFocus
Summit Therapeutics stock gains on insider buy (SMMT:NASDAQ) - Seeking Alpha
Truist maintains Buy on Summit Therapeutics, $35 target - Investing.com
Cantor Fitzgerald maintains Overweight on Summit Therapeutics - Investing.com
Summit Therapeutics Co-CEOs Make Bold Stock Purchases! - TipRanks
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China - TipRanks
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc.SMMT - MarketScreener
We Think Summit Therapeutics (NASDAQ:SMMT) Can Easily Afford To Drive Business Growth - Yahoo Finance
(SMMT) Technical Data - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Agrees to $127K Settlement in Wage Dispute - USA Herald
Summit Therapeutics Strengthens Team with Strategic Stock Options Worth $3.4M - Stock Titan
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Summit Therapeutics (SMMT) Surpasses Nvidia with High Hopes for Cancer Drug - GuruFocus
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months - Yahoo Finance
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):